- Zervimesine’s impact on debilitating DLB behavioral symptoms highlighted in podium presentation -- Plasma p-tau217 levels can identify Alzheimer’s patients most likely to benefit from zervimesine treatment -- Plasma and CSF biomarkers support zervimesine’s impact on Alzheimer’s disease biology - PURCHASE, N.Y., July 29, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, presente ...

PITTSBURGH, July 21, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, published results of a proteomics analysis from the Phase 2 ‘SEQUEL’ COG0202 Study of zervimesine (CT1812) in adults with mild-to-moderate Alzheimer's disease. The manuscript, titled Identification of Cerebrospinal Fluid Pharmacodynamic Biomarkers and Molecular Correlates of Brain Activity in a Phase 2 Cli ...

Core Insights - Cognition Therapeutics, Inc. conducted a positive end-of-Phase 2 meeting with the FDA regarding zervimesine (CT1812) for Alzheimer's disease treatment [1][2] - The SHINE Study demonstrated safety and tolerability, meeting its primary endpoints with 153 participants [4] - Zervimesine has been adopted as the United States Adopted Name (USAN) for CT1812 [3] Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders [6] - The company is advancing zervimesine through various clinical studies, including ongoing trials for dementia with Lewy bodies and early Alzheimer's disease [6] Study Details - The SHINE Study was a double-blind, placebo-controlled Phase 2 trial that enrolled 153 adults with mild-to-moderate Alzheimer's disease, assessing cognitive and functional changes [4] - The study received approximately $30 million in grant support from the National Institute on Aging [5] Drug Mechanism - Zervimesine is an investigational oral medication that targets the toxic effects of Aβ and ɑ-synuclein proteins associated with neurodegenerative diseases [2][6] - The drug aims to slow disease progression and improve the quality of life for patients suffering from Alzheimer's and dementia with Lewy bodies [2]

PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer’s Clinical Trials Consortium (ACTC), with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health. Christopher van Dyck, ...

Core Insights - Cognition Therapeutics, Inc. is advancing zervimesine (CT1812) into a Phase 3 program for mild-to-moderate Alzheimer's disease and has filed for breakthrough therapy designation for dementia with Lewy bodies (DLB) [1][2] Group 1: Clinical Development - An end-of-Phase 2 meeting with the FDA is scheduled for July 9, 2025, to discuss the Phase 2 'SHINE' study results and plans for a Phase 3 program for zervimesine in Alzheimer's disease [1] - The company is also progressing with an expanded access program for zervimesine in DLB, which has garnered high interest from former SHIMMER study participants [3] Group 2: Drug Information - Zervimesine (CT1812) is an investigational oral medication aimed at treating neurodegenerative diseases, specifically Alzheimer's disease and DLB, by potentially interrupting the toxic effects of protein buildup in the brain [4] - The drug has been generally well tolerated in clinical studies to date [4] Group 3: Company Overview - Cognition Therapeutics, Inc. focuses on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and has completed Phase 2 studies for zervimesine in multiple conditions [6]

Core Viewpoint - Cognition Therapeutics, Inc. is advancing its investigational drug zervimesine (CT1812) for the treatment of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB), with an end-of-Phase 2 meeting scheduled with the FDA to discuss Phase 2 study results and plans for a Phase 3 program [1][2][8] Group 1: Clinical Development - The company will hold an end-of-Phase 2 meeting with the FDA on July 9, 2025, to review the Phase 2 'SHINE' study results of zervimesine in Alzheimer's disease [1] - Cognition is also moving forward with plans for a registrational program for DLB based on positive results from the Phase 2 'SHIMMER' study [2] - An expanded access program for zervimesine in DLB is underway, with high interest from former SHIMMER participants [3] Group 2: Drug Information - Zervimesine (CT1812) is an oral, once-daily investigational drug targeting neurodegenerative diseases, specifically Alzheimer's and DLB, by potentially interrupting the toxic effects of harmful proteins in the brain [4] - The drug has been generally well tolerated in clinical studies to date [4] - The USAN Council has adopted zervimesine as the official name for CT1812 [5] Group 3: Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [6] - The company has completed Phase 2 studies for zervimesine in multiple conditions, including DLB and Alzheimer's disease, and is currently conducting an ongoing Phase 2 study in early Alzheimer's disease [6]

Dr. James Galvin of the University of Miami to Serve as Lead Investigator First Site Initiated: Banner Sun Health Research Institute PURCHASE, N.Y., June 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced today it has received an anonymous philanthropic donation to substantially fund an expanded access program (EAP) for people with dementia with Lewy bodies (DLB ...

Core Insights - Cognition Therapeutics, Inc. has released its tenth episode of the Conversations video podcast, focusing on the lived experiences of caregivers for patients with Lewy body dementia [1][2] - The podcast features insights from caregivers and physician experts involved in Cognition's Phase 2 'SHIMMER' study, discussing the challenges and symptoms associated with dementia with Lewy bodies (DLB) [2] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders [8] - The company is currently investigating its lead candidate, zervimesine (CT1812), in clinical programs for DLB and Alzheimer's disease [8][11] SHIMMER Study Details - The SHIMMER study is a Phase 2 clinical trial that enrolled 130 adults with mild-to-moderate DLB, randomized to receive either zervimesine or placebo for six months [6] - The study utilized various assessment tools, including the Neuropsychiatric Inventory and the Montreal Cognitive Assessment, to measure cognitive performance and symptoms [6] - The SHIMMER study received approximately $30 million in funding from the National Institute on Aging and was presented at the International Lewy Body Dementia Conference in January 2025 [7]

Core Insights - Cognition Therapeutics, Inc. reported promising preclinical data on zervimesine (CT1812) at the ARVO conference, indicating its potential to protect retinal pigment epithelial (RPE) cells from damage in dry age-related macular degeneration (dry AMD) [1][2][3] Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics for age-related degenerative disorders of the central nervous system [9] - The company is currently investigating zervimesine in clinical programs for dementia with Lewy bodies and Alzheimer's disease, including the ongoing START study in early Alzheimer's disease [9] Product Details - Zervimesine is an investigational oral drug candidate that has shown the ability to reach therapeutic concentrations in the eye and is being studied for its effects on retinal cell health [2][4] - The drug binds to the sigma-2 receptor (TMEM97), which is crucial for retinal cell lipid uptake, a process impaired in dry AMD [2][3] - In a Phase 2 clinical trial, zervimesine slowed the rate of geographic atrophy lesion growth by 28.6% compared to placebo, resulting in smaller lesions for treated patients [4] Disease Context - Dry AMD accounts for up to 90% of age-related macular degeneration cases and leads to irreversible vision loss due to the death of retinal cells [6] - The disease is characterized by the accumulation of oxidized lipids and drusen, which damage RPE cells and contribute to vision loss [3][6] Research Findings - Preclinical research supports zervimesine's potential to protect retinal cells from oxidized lipids and enhance cellular function in degenerative diseases [2][3][4] - The drug has also shown robust clinical results in studies involving Alzheimer's disease and dementia with Lewy bodies, indicating its broader therapeutic potential [4][7]

Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate zervimesine’s potential across degenerative disease indications PURCHASE, N.Y., May 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported topline results today from the Phase 2 COG2201 ‘MAGNIFY’ trial of zervime ...